Nelivaptan - HMNC Brain Health
Alternative Names: BH 200Latest Information Update: 26 Jun 2023
At a glance
- Originator Sanofi
- Developer HMNC Brain Health
- Class Antidepressants
- Mechanism of Action Vasopressin 1b receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Major depressive disorder
Most Recent Events
- 28 Mar 2023 Phase-II clinical trials in Major depressive disorder in Germany, Bulgaria, Spain (PO) (EudraCT2022-002757-26)
- 28 Mar 2023 Phase-II clinical trials in Major depressive disorder (In adults, In the elderly) in Lithuania (PO) (EudraCT2022-002757-26)
- 20 Oct 2022 HMNC Brain Health plans a phase II trial for Major depressive disorder in the first half of 2023